| Objectives In order to explore the optimal lipid regulation scheme for ACS patients,we observed the blood lipid,inflammatory factors and short-term prognosis of the patients in the two groups by using ezemeb and atorvastatin respectively and double dose statins alone.Methods 120 ACS patients admitted to the Cardiovascular Department of Tangshan Worker's Hospital from December 2018 to November 2019,then randomly divided into the combined drug group and the atorvastatin group.60 patients in the combination medication group were given atorvastatin 20mg/night and ezetimibe 10mg/day.60 patients in the atorvastatin group received only 40 mg of atorvastatin per night.Blood lipid indicators,hs-CRP and Lp-PLA2 levels were measured before and 3 months after the first treatment,the total number of cumulative adverse drug reactions and the number of major cardiovascular adverse events occurred within 3 months were collected and summarized.SPSS17.0 software was used for statistical analysis of the data.Measurement data in line with normal distribution are expressed as mean ± standard deviation((?)±s),while counting data are expressed as frequency.t test was used for comparison between groups before and after treatment.The statistical data rate was tested by ?~2 test.P<0.05 was considered statistically significant.Results 1 The basic data of the two groups,such as sex ratio,age,smoking history,BMI,family history,were statistically analyzed.There was no difference between the two groups.2 The concentrations of ALT,AST,TC,TG,LDL-C,HDL-C,Lp-PLA2 and hsCRP before treatment were compared between the two groups,and there was no significant difference in the above indexes between the two groups.3 After treatment,in experimrntal group,TC decreased from 5.81 ± 0.47 to 5.40 ± 0.96,TG decreased from 1.97 ± 0.42 to 1.62 ± 0.60,LDL-C decreased from 3.54 ± 0.51 before administration to 3.03 ± 0.48,and HDL-C increased from 1.07 ± 0.17 to 1.34 ± 0.14;in the control group,TC decreased from 5.95 ± 0.44 to 5.69 ± 0.61 before and after administration,TG decreased from 2.09 ± 0.41 to 1.86 ± 0.63,LDL-C decreased from 3.56 ± 0.56 before administration to 3.24 ± 0.44,and HDL-C increased from 1.09 ± 0.17 to 1.29 ± 0.18.The TC,TG,and LDL-C were compared between the two groups after administration,the P values were 0.049,0.033,0.015,and P<0.05,and the differences were statistically significant,combined with the mean values,it can be seen that the TC,TG,and LDL-C in the combination group reduction was greater than that of the statin group,and the combination group achieved better results in reducing lipids.HDL-C was compared between the two groups after administration,P value was 0.069,P>0.05,the difference was not statistically significant,indicating that there was no significant difference between the two groups in increasing HDL-C.4 After administration,hs-CRP in the experimental group decreased from 6.01 ± 1.83 to 5.21 ± 1.84,and Lp-PLA2 decreased from 181.42 ± 8.19 before treatment to 169.52 ± 8.30;hs-CRP in the control group decreased from 6.16 ± 1.69 to 5.86 ± 1.71,LpPLA2 decreased from 184.20 ± 7.59 before treatment to 170.10 ± 7.71.After comparing the two groups of hs-CRP and Lp-PLA2 after administration,the P values were 0.049 and 0.016,P<0.05,the difference was statistically significant,combined with the mean values before and after treatment the two groups,it can be seen that the experimental group hsCRP and Lp-PLA2 decreased even more.5 There was no significant difference in liver function and kinase between the combination group and the atorvastatin group.Conclusions 1 For patients with ACS,compared with the atorvastatin group,the combination group has more significant advantage in lipid-lowering and inflammatory response control,but it can not reduce the incidence of cardiac adverse events.2 The combination medication group and atorvastatin group have good safety and tolerability for patients.Figure 6;Table 11;Reference 112... |
PDF Full Text Request